All obviously true. I love my Jewish friends. Am actually temperamentally philosemitic. But this is the straw that broke the camel's back for me with Zionism and Rabbinic Judaism, who are the heirs to the Pharisees, about whom Jesus warned us in the Gospels.
They should use it. This isn’t a “Democrats pounce” situation. I don’t like the far left or the Democrats any more than you do, but the Iran War is more than a political millstone, it’s a genuine catastrophe. Trump made the US military an extension of the IDF, and the admin doesn’t even bother trying to deny it because they can’t articulate any other reason for the war. The manner in which the war was launched made Pearl Harbor look honorable, which might be outside the moral understanding of the Israelis or someone of Trump’s character, but it still matters to some of us. The US Navy sank an unarmed ship leaving a friendly naval conference, then left the sailors to drown, ffs. Americans like that man’s wife are dead because the President put the US military at the disposal of Israel against all advice from his own administration, only for Israel to leave us to fight Iran alone while they conquered southern Lebanon instead. On top of it all, we lost. It’s hard to imagine the Democrat Party doing any more reprehensible, or more strategically and economically destructive, than what this administration has done.
2
73
We should have never gotten rid of controlling high beams with our feet.
Why DID we ditch that?
1
30
🤖 Made with AI
A 37-year-old woman with 10 years of abdominal pain.
—The AI makes the diagnosis and recommends a successful treatment.
—The physician "diagnosed a patient with a condition I had never diagnosed before and started treatment largely on the basis of the output of a chatbot."
In today's @NEJM
nejm.org/doi/full/10.1056/NE…
Greengrocer retweeted
I dont know about details of why she was blocked
All I know is if you care about evidence and science of regulatory decisions, Adam is probably the last person I would read
He's like how Jim Cramer covers finance or Skip Bayless does basketball
Misses the core function of what FDA should do and focuses on business and finances
Why did Adam Feuerstein block me?
Only Adam could say for sure. But I suspect two exchanges we had on X—one about Tavneos in July and another about UniQure's Huntington's disease gene therapy in March—may have contributed.
I find the block genuinely disappointing, not least because I've long found Adam's reporting interesting and valued being able to engage with it.
I don't expect journalists to answer every question or agree with every criticism. But I do think there is a meaningful difference between declining to engage with someone and blocking that person from participating in discussions about one's reporting.
And I think the substance of these exchanges matters.
1. Tavneos: A public assertion that went unexplained
In July, Adam responded to someone else's post about the Tavneos controversy, suggesting that it wasn't entirely certain whether the clinical trial had been falsified.
That caught my attention.
Given the documented evidence of data-integrity problems and regulatory failures surrounding the trial, I wanted to understand what, specifically, Adam believed remained uncertain.
He had publicly introduced that qualification into the discussion. I thought it was reasonable to ask him to explain the basis for it.
I asked twice. He didn't respond to either question.
I don't expect journalists to answer every question directed at them. But when an influential reporter voluntarily makes a public assertion casting uncertainty on something as consequential as clinical trial falsification, I think it's fair to ask what evidence supports that qualification.
And I think it's disappointing when a substantive question like that goes unanswered.
2. UniQure: The missing regulatory context and the treatment of Vinay Prasad
The more substantial exchange occurred in March, during the controversy surrounding UniQure's experimental Huntington's disease gene therapy, AMT-130.
For those unfamiliar with the story, Huntington's is a devastating, progressive neurological disease. AMT-130 is an experimental gene therapy administered directly into the brain.
In September 2025, UniQure announced results suggesting that AMT-130 had slowed disease progression by approximately 75% over three years compared with an external control group drawn from a natural-history database.
The results generated considerable excitement, particularly among patients and families facing a disease without an approved treatment shown to slow its progression.
But there was an important complication.
The trial had originally included a randomized, sham-surgery control group.
Earlier results from that comparison had not demonstrated a statistically significant benefit on the reported measures. After one year, participants assigned to sham surgery were permitted to receive AMT-130, eliminating the original randomized comparator for longer-term follow-up.
UniQure subsequently relied on comparisons with patients from an external natural-history database.
That distinction matters enormously.
An external comparison can be informative, particularly in rare diseases where randomized trials present practical and ethical challenges. But it also raises difficult questions about whether the groups are truly comparable and whether apparent benefits can be attributed to treatment.
In March 2026, UniQure announced that FDA continued to consider its existing evidence insufficient to support a marketing application and was recommending a new randomized, sham-controlled trial.
The company characterized the agency's position as a reversal of earlier regulatory guidance.
STAT reported the dispute, including the company's frustration and the implications for FDA's stated commitment to regulatory flexibility.
What I thought was missing was sufficient context about why FDA might have reached that position.
The earlier randomized findings weren't an incidental historical detail. They were directly relevant to evaluating the reliability of the later externally controlled results.
And that became increasingly clear as additional reporting emerged.
3. What the FDA's concerns actually were
On March 3, Adam published a follow-up STAT article quoting an unnamed senior FDA official who said agency reviewers were unconvinced that AMT-130 provided therapeutic benefit.
The article conveyed the FDA's skepticism, but it still offered relatively little explanation of the underlying scientific objections.
On March 5, Fierce Biotech published a much more detailed account of a briefing with a senior FDA official.
That reporting helped illuminate the actual regulatory disagreement.
The FDA's concerns included the substantial variability in Huntington's disease progression, the subjectivity of certain clinical outcomes, potential placebo effects, and the limitations of comparing treated patients with an external natural-history population.
But one question was particularly important:
Why did the externally controlled analysis suggest a benefit at one year when the randomized comparison had not demonstrated one?
That apparent discrepancy went directly to the reliability of the external comparator.
The FDA official questioned whether the natural-history patients provided a sufficiently comparable control group. UniQure, meanwhile, maintained that the early randomized study was too small and too short to reliably demonstrate the treatment's effect on disease progression.
These were legitimate scientific questions with enormous implications for patients, the company, and the regulatory standard being applied.
They also helped explain why the FDA's position could not be evaluated simply by asking whether the agency had become less flexible.
To me, this was essential context for understanding the controversy.
I was grateful for Fierce Biotech's reporting because it allowed readers to examine the reasoning rather than simply choose between competing narratives.
4. Adam subsequently acknowledged that important context was missing
Here's something I find particularly significant.
In his March 5 Biotech Scorecard newsletter, Adam published a Q&A addressing reader questions about his UniQure reporting.
One reader criticized the lack of detail about the FDA's objections.
Adam responded:
"This is a totally valid criticism."
He went on to explain that he had omitted the details largely because they complicated the narrative.
He then provided precisely the kind of regulatory context I had found missing: the earlier sham-controlled findings, the loss of the randomized comparator after crossover, and the FDA's concerns about the validity of the external comparison.
I appreciate that he acknowledged the criticism and provided the additional information.
But I also think the acknowledgment is important.
It demonstrates that questioning the adequacy of the initial reporting wasn't an unreasonable objection or a failure to appreciate STAT's previous coverage.
It was a substantive concern about what readers needed to understand the FDA's position.
5. How our exchange began
On March 7, someone complimented my coverage of the FDA, specifically noting my willingness to examine the evidence beneath the story rather than simply repeat prevailing narratives.
Adam entered the conversation to point out that STAT had been covering UniQure for years.
He linked to articles from 2022, 2023, and 2025.
That was true. STAT had covered the development of AMT-130 extensively.
But it wasn't the point I was making.
The existence of earlier reporting doesn't necessarily mean that a subsequent article adequately contextualizes a new development.
My criticism wasn't that STAT hadn't covered the story. It was that readers shouldn't have to reconstruct the regulatory reasoning from years of previous articles to understand what was happening in March.
I tried to explain that distinction.
I acknowledged the earlier coverage and clarified that my criticism concerned the framing of the current controversy, particularly the absence of the randomized findings and the FDA's underlying scientific reasoning.
Adam responded that my failure to acknowledge STAT's years of reporting was not his concern.
But I had acknowledged it.
When I tried again to distinguish the historical coverage from the contemporaneous framing, he dismissed my concern about how the story came across to readers.
At that point, the exchange became increasingly contentious.
My own responses became sharper. I criticized what I saw as his abrasive, dismissive replies and described his earlier podcasting as snarky.
I don't pretend that my tone remained entirely restrained. But I had initially tried to explain a substantive distinction that I felt he wasn't addressing.
And it's worth remembering how the exchange began: I hadn't sought Adam out to confront him. He had entered a conversation that began with someone complimenting my work.
6. The treatment of Vinay Prasad: A separate concern about journalistic judgment
Another aspect of Adam's reporting troubled me, and it concerned the treatment of Vinay Prasad.
In his March 3 article, Adam quoted a senior FDA official speaking on condition of anonymity. Other reporting, including Fierce Biotech's account of an FDA briefing, likewise referred to an unnamed senior official.
In his March 5 newsletter, Adam explicitly defended his decision to grant the official anonymity.
Yet in a March 6 article, Adam continued to describe the individual as an anonymous senior FDA official while reproducing remarks in which the official identified himself as a professor, practicing hematologist-oncologist, and someone who missed hosting his podcast.
Those details appeared to point rather unmistakably to Vinay Prasad.
Adam then promoted the article on X, teasing what readers might learn about the official.
I found that strikingly inconsistent.
What's the point of maintaining anonymity in the text while simultaneously publishing details that effectively identify the person—and then drawing attention to them?
The article's derisive framing and the way Adam promoted it only compounded my discomfort. My concern wasn't that Prasad should be shielded from scrutiny or criticism. It was whether this reflected sound journalistic judgment.
I initially chose not to raise this concern during our exchange. I eventually did as the conversation became more contentious.
7. Why I find the block disappointing
What bothers me isn't that Adam disagreed with my assessment of his reporting.
Disagreement is inevitable, particularly when discussing complex regulatory decisions involving uncertain evidence, serious diseases, and competing views of what constitutes sufficient proof.
Nor do I think every journalist owes every reader a response.
But I do think journalists—especially influential reporters covering science and medicine—should be receptive to reasonable questions about their reporting and public statements.
That doesn't mean accepting every criticism. It doesn't mean tolerating harassment or personal attacks.
It means recognizing that substantive disagreement is part of the conversation.
What makes this particularly disappointing is that I genuinely valued Adam's reporting. I found it interesting, followed it regularly, and appreciated the opportunity to engage with it.
I would have preferred that we could simply disagree.
If Adam doesn't want to engage with me, that's entirely his choice.
But I wish that choice didn't extend to blocking me from commenting on or questioning his work.
And I think it's a shame if a good-faith attempt to discuss the evidence ultimately ends this way
As a subscriber to a Big Five orchestra, I'm always grateful when a program is about the music.
There's money on the sidewalk for the band that doubles down on this.
The phrase “artistic excellence” was deleted from an early draft of the Boston Symphony Orchestra’s strategic plan.
In September 2025, conductor Andris Nelsons asked that it be restored, because excellence is the “indispensable engine for everything the BSO does.”
Five months later, the board voted to terminate his contract.
@HMDatMI on the BSO's power struggle over diversity, ideology, and organizational control ⬇️ city-journal.org/article/cla…
10
Greengrocer retweeted
Biggest loser in American politics.
Could have been the left-wing Trump and a real threat to Trump but didn’t have the cojones to stick with his “mass immigration is a Koch Brothers thing.” Immigration-restrictionist left populism could have been his ticket.
Greengrocer retweeted
🔸 November 13 - Saint John Chrysostomos 🔸
Today, we commemorate Saint John Chrysostom, Archbishop of Constantinople and one of the Three Hierarchs along with St Basil the Great and St Gregory the Theologian. St John was born in Antioch in 347. His father, a military commander, died when he was young, and so he was raised by his pious mother St Anthousa. After excelling in philosophy, rhetoric and the sciences, he studied theology under Diodorus of Tarsus.
Around 375, he became a hermit, and spent 2 years living in the wilderness in a cave in complete silence, fasting and praying constantly, scarcely sleeping, and committing the Holy Scriptures to memory. Poor health from such intense asceticism forced him to return to Antioch. He was ordained a deacon by St Meletios the Patriarch of Antioch in 381, and a priest in 386. He quickly gained popularity for his inspiring and eloquent preaching which stirred the hearts of his listeners, and earned him the name “Golden-Mouthed” (“Chrysostom”).
In 397, he left Antioch after being appointed Archbishop of Constantinople. As Patriarch, he governed the Church with unequalled zeal and wisdom. He sent missionaries to the pagan Goths and Scythians, and to spread the Gospel throughout Phoenicia, Persia, and Asia Minor. St John emphasised almsgiving and zealously fulfilled the Lord’s command to care for the needy. He built hospices for the sick, hostels for pilgrims, and extended the Church’s charitable works to provide daily sustenance to the poor, widows and orphans.
He also worked to enhance the sanctity of church services, and refined the Divine Liturgy which bears his name. He boldly denounced the dissolute morals and corruption of the imperial class, especially Empress Eudoxia for her lavish and arrogant lifestyle, her unjust seizure of property from the poor, and the erection of a silver statue of herself near Hagia Sophia. For his outspoken and bold criticism of the Empress, St John was deposed and exiled to the Caucasus in Georgia where he reposed in 407.
His surviving works include over 700 sermons, 250 letters, and many other biblical commentaries, moral discourses, and theological treatises.
The entire company has been replaced by Indians, so now is when they trot out the white Notre Dame grad.
I want to share what we know so far. This was not a cyberattack or an issue caused by AI tooling. Our amazing team was able to work through a very challenging situation to restore service.
Our investigation points to technical challenges and failure modes (cascading failures + thundering herds at our network perimeter) that made recovery more difficult than normal. I'm working closely with the engineering team to complete the full post-mortem. We will publish the post-mortem shortly covering the step-by-step timeline and our many repair items to avoid similar outages in the future.
We take our responsibility to our customers seriously and will do everything we can to learn from this and prevent it going forward.
24
Hansen is wise about many things, but not this.
The war on Iran could never have been seriously considered a potential Jacksonian intervention. Iran was part of the OG Axis of Evil, said assignation coming from the neocons.
After the midterm wipeout, divisive blame-gaming erupted on the Right. One particularly bitter divide was over supposed “neocon” interventionism and the Iran war.
But who are—or were—the neocons, and what is neoconservatism?
victorhanson.com/neocons-neo…
17
Greengrocer retweeted
This is a perfectly acceptable monologue without a shred of racism but they put “SS” face tattoos on them and shave their heads so that normies nod along and say “hmmm yes the American government SHOULDN’T prioritize Americans”
You have been propagandized
Greengrocer retweeted
The idea that Senate GOP could get this brutal ass-whooping and respond by rolling its decrepit leadership back into power is honestly EMBARRASSING. “Let’s keep the same pathetic leadership.” HAVE SOME DECENCY! Step down as a matter of honor! Stop crapping on your own voters!
Facts. I'm a chunky dude. Love all food. But I would be at least 300 pounds if I didn't put off eating until the end of the day most days.
It's much easier for me to not start eating than it is to stop eating once I've started.
Replying to @KenDBerryMD
OMG that’s me. I can eat 0 cookies or all the cookies. I have to choose every single time I see cookies.
8
One of the bigger problems with DEI nonsense is it invalidates the achievements of those who didn't need a thumb on the scale. And, importantly, it's perfectly *rational* for people to assume a person who *could* fill a DEI quota *is* filling a DEI quota.
Guys, we need to have an honest conversation about DEI. And some fellow conservatives aren’t going to like this.
My son attends @ERAU_Daytona, arguably the top flight school in the world. He earned a 4.0 GPA last semester and just scored a 97 on his commercial pilot exam.
He’s 6’3”, confident, and has sailed with me through ocean storms so violent I probably should have been arrested for bringing him aboard. We’ve hiked deep into the wilderness for days with nothing but backpacks.
I don’t say this to brag. I say it because the kid is a rock star.
He’s exactly the kind of young man you’d want to see at the end of the jetway.
Now let’s talk about the tragic Learjet crash that killed nine people.
The captain was Jeff Gregory, 55, a white man with decades of experience and the gray hair and seasoned appearance that inspire confidence.
His copilot was Nathalia Gadelha Filgueiras, a 20-year-old woman.
And immediately people started screaming DEI.
That makes my blood boil.
I’m DEAD set against DEI quotas. I believe cockpit seats should be earned through competence, judgment, and merit. Not race or gender.
But if you look at a female pilot and automatically assume she’s a DEI hire, YOU ARE DOING EXACTLY WHAT YOU CLAIM TO OPPOSE.
Consider this:
My son is 20. She was 20.
My son has hundreds of flight hours. She reportedly had over 1,300.
My son is working on his commercial certificate. She earned hers as a teenager.
My son flies single-engine piston aircraft. She was flying a JET the military uses.
Put it in baseball terms: My son is the college phenom with every Major League scout in the stands, watching his every move and predicting a brilliant future.
But she? At the same age, she was already batting cleanup for the Scranton/Wilkes-Barre RailRiders, the New York Yankees’ Triple-A team.
A the same age, she was operating at an entirely different level of professional aviation.
Was she a great pilot? YES. You don’t move up that fast if you suck. The testing is just too hard.
Bringing DEI into this is just wrong.
YES there are DEI pilots.
YES some airlines have pushed mediocre women too fast and too far.
But Nathalia wasn’t one of them.
I’ve discussed this extensively with @JavonPrice. I’m a proud dues-paying member of the Organization of Black Maritime Graduates.
What I love about them is they don’t give a damn about your skin color when it comes to joining or getting a scholarship. They want outstanding mariners.
Yet whenever I promote an exceptional Black graduate, someone inevitably says:
“We don’t need another DEI hire.”
Or, “Don’t tell me to hire him because he’s Black.”
I’M NOT.
I’m telling you to hire him because he’s a damn good mariner.
Here’s what conservatives need to understand:
You cannot demand a meritocracy while refusing to recognize merit because liberals have rigged the game.
You cannot condemn identity politics and then judge someone by their identity.
You have to be color blind but also make absolutely certain you give everyone a fair assessment and don’t swing the other way.
And if your first thought when you see a woman or minority is “DEI hire,” that does NOT make you racist. DEI has created legitimate concerns about merit. But it DOES mean you have a bias and it’s YOUR responsibility to recognize it, challenge it, and judge the individual on merit.
Do not compensate by giving the person extra points on their job interview but 💯 DO spend a little more time digging into their resume to see if they are a rockstar.
As a ship captain, I don’t care whether the officer standing watch beside me is Black, white, male, or female.
I care whether they can do the damn job.
ONE STANDARD. FOR EVERYONE.
Nine people died in that crash. Their families deserve answers, not political accusations.
The ocean doesn’t care who you are.
Gravity doesn’t care who you voted for.
If we’re going to fight for meritocracy, we’d damn well better defend merit wherever we find it.
1
9
A bunch of white people who voted for Obama, then Trump, told Trump to go to hell.
Now, does that make meticulous logical sense seeing how Trump wasn't on the ballot? No. But voting in the aggregate is rarely logical.
This electorate was *more* white than 2024.
2024 - 71% of voters were white
2026 - 73% of voters were white
So much for the "millions of mass immigrants suddenly voted without anyone seeing them" theory
9






































